GSK clinical Study results
GlaxoSmithKline plc [LSE/NYSE: GSK] today announced that a Phase III study of the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib), compared to single agent therapy with Tafinlar in patients with BRAF V600 E or K mutation positive unresectable or metastatic melanoma, met its primary endpoint of Progression Free Survival (PFS) (p20%) adverse events were pyrexia, fatigue, nausea, headache, chills, diarrhoea, arthralgia, rash, hypertension, and vomiting. Full study results will be presented at an upcoming scientific meeting.
“We are pleased to report that the first of our phase III studies investigating the combination of Tafinlar and Mekinist met its primary endpoint. These results, along with data we expect to receive later in the year from our Phase III study comparing the combination to vemurafenib, will increase the body of evidence on the safety and efficacy of this combination in appropriate patients with melanoma, ” said Dr Rafael Amado, Senior Vice President Oncology R&D, GSK.
The Phase III programme for dabrafenib and trametinib in BRAF V600E/K metastatic melanoma comprises two studies: COMBI-d (also known as MEK MEK115306) and COMBI-v (also known as MEK116513).
· Today’s results are from COMBI-d (NCT01584648) a Phase III, randomised, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in patients with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation-positive cutaneous melanoma. The primary endpoint of the study is progression-free survival and patients will be followed for overall survival. The study randomised 423 patients from investigative sites in Australia, Europe, North and South America.
· COMBI-v (NCT01597908) is a Phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in patients with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation-positive cutaneous melanoma. The primary endpoint of the study is overall survival and results are anticipated in 2014.
Combination use of Tafinlarand Mekinist in patients with BRAF V600E or K metastatic melanoma is approved for use only in the US and is not approved anywhere else in the world.
For EU SPC for the approved indication for Tafinlar®:
For US Prescribing Information and Patient Information Leaflet for Mekinist:
For US full Prescribing Information and Medication Guide for Tafinlar:
Trametinib was in-licensed by GSK in 2006. GSK holds the worldwide exclusive rights to develop, manufacture and commercialise Mekinist, while Japan Tobacco retains co-promotion rights in Japan.
Important Safety Information for Mekinist and Tafinlar combination
Tafinlar and Mekinist are registered trade marks of the GSK group of companies.
You might also like
Prost-P10x. Professional Strength Natural Prostate Supplement. Available without a Prescription. Doctor Formulated by Leading Naturopathic Urologist. Graminex Flower Pollen Extract, Quercetin, Meriva® Curcumin, DIM, Beta-sitosterol, Saw Palmetto + 6 Additional Extra Strength Natural Ingredients For Maximum Prostate Health. Therapeutic Dose (3320+mg/1000 IU), Professional Grade, 100% Natural, Maximum Strength for Men Looking for Results. Proudly Developed in the USA.
Health and Beauty (Douglas Laboratories)
BMC Medical Research Methodology at the 35th Annual Conference of the .. — BMC Pediatrics
The conference will focus on issues such as design and analysis of clinical trials, methods in biostatistics and development of clinical prediction models.
Curcumin Longvida Powder by Nutrivene (30 grams)
Health and Beauty (Nutrivene)
Pure Encapsulations - CurcumaSorb - 180ct
Health and Beauty (Pure Encapsulations)
Thorne Research, Meriva-500 (120 Caps) Pack of 2
Health and Beauty (Thorne Research)
Gaia Herbs Turmeric Supreme Pain P.M, 60 Count
Health and Beauty (Gaia Herbs)
What were the clinical results of the tuskegee study?
The results of the Tuskegee study are actually quite broad and too in depth to put into the text message character limit.